TY - JOUR T1 - Polaprezinc Prevents Oral Mucositis in Patients Treated with High-dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation JF - Anticancer Research JO - Anticancer Res SP - 7271 LP - 7277 VL - 34 IS - 12 AU - HIROKO HAYASHI AU - RYO KOBAYASHI AU - AKIO SUZUKI AU - MASASHI ISHIHARA AU - NOBUHIKO NAKAMURA AU - JUNICHI KITAGAWA AU - NOBUHIRO KANEMURA AU - SENJI KASAHARA AU - KIYOYUKI KITAICHI AU - TAKESHI HARA AU - HISASHI TSURUMI AU - HISATAKA MORIWAKI AU - YOSHINORI ITOH Y1 - 2014/12/01 UR - http://ar.iiarjournals.org/content/34/12/7271.abstract N2 - We have previously reported that polaprezinc in sodium alginate suspension (P-AG) inhibited the incidence of oral mucositis induced by radiochemotherapy in patients with head and neck cancer. The present study was designed to investigate whether P-AG prevents oral mucositis in all patients (36 patients) with hematological malignancy receiving high-dose chemotherapy and radiotherapy followed by hematopoietic stem cell transplantation (HSCT). P-AG dramatically reduced the incidence of moderate-to-severe oral mucositis as compared to the control group treated with azulene gargle (20% versus 82% for grade≥2, p<0.01; 0% versus 45% for grade≥3, p<0.01). Pain associated with oral mucositis was also significantly (p=0.004) relieved by P-AG, resulting in a reduction in the use of analgesic agents (28% versus 73%, p=0.025). The incidence of xerostomia and taste disturbance tended to be lowered but not significantly by P-AG. On the other hand, P-AG had no influence on the incidence of other adverse events, tumor remission rate or the survival rate. Therefore, P-AG was found to be highly effective in preventing oral mucositis induced not only by radiochemotherapy for head and neck cancer but also by high-dose chemotherapy and radiotherapy followed by HSCT. ER -